PNC Financial Services Group’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $235K | Sell |
9,122
-98
| -1% | -$2.01K | ﹤0.01% | 2353 |
|
|
2026
Q1 | $177K | Buy |
9,220
+739
| +9% | +$14.7K | ﹤0.01% | 2412 |
|
|
2025
Q4 | $140K | Buy |
8,481
+191
| +2% | +$3.22K | ﹤0.01% | 2563 |
|
|
2025
Q3 | $120K | Buy |
8,290
+54
| +0.7% | +$776 | ﹤0.01% | 2674 |
|
|
2025
Q2 | $115K | Buy |
8,236
+4,494
| +120% | +$63.3K | ﹤0.01% | 2610 |
|
|
2025
Q1 | $50.9K | Sell |
3,742
-48
| -1% | -$920 | ﹤0.01% | 3082 |
|
|
2024
Q4 | $77.2K | Buy |
3,790
+885
| +30% | +$22.7K | ﹤0.01% | 2836 |
|
|
2024
Q3 | $84.6K | Buy |
2,905
+536
| +23% | +$13.3K | ﹤0.01% | 2774 |
|
|
2024
Q2 | $55K | Buy |
2,369
+714
| +43% | +$13.7K | ﹤0.01% | 2974 |
|
|
2024
Q1 | $34K | Sell |
1,655
-831
| -33% | -$15.6K | ﹤0.01% | 3176 |
|
|
2023
Q4 | $53.3K | Buy |
2,486
+807
| +48% | +$16K | ﹤0.01% | 2936 |
|
|
2023
Q3 | $34.6K | Sell |
1,679
-292
| -15% | -$7.41K | ﹤0.01% | 3141 |
|
|
2023
Q2 | $58.2K | Buy |
1,971
+515
| +35% | +$14.5K | ﹤0.01% | 2976 |
|
|
2023
Q1 | $33.5K | Sell |
1,456
-213
| -13% | -$5.86K | ﹤0.01% | 3202 |
|
|
2022
Q4 | $46.4K | Buy |
1,669
+768
| +85% | +$22.9K | ﹤0.01% | 3025 |
|
|
2022
Q3 | $27K | Buy |
901
+83
| +10% | +$2.7K | ﹤0.01% | 3302 |
|
|
2022
Q2 | $24K | Sell |
818
-20
| -2% | -$524 | ﹤0.01% | 3402 |
|
|
2022
Q1 | $27K | Sell |
838
-614
| -42% | -$21.1K | ﹤0.01% | 3433 |
|
|
2021
Q4 | $65K | Buy |
1,452
+241
| +20% | +$11.4K | ﹤0.01% | 2957 |
|
|
2021
Q3 | $61K | Buy |
1,211
+282
| +30% | +$15.9K | ﹤0.01% | 2943 |
|
|
2021
Q2 | $73K | Buy |
929
+12
| +1% | +$742 | ﹤0.01% | 2838 |
|
|
2021
Q1 | $52K | Sell |
917
-10
| -1% | -$669 | ﹤0.01% | 2959 |
|
|
2020
Q4 | $78K | Buy |
927
+3
| +0.3% | +$181 | ﹤0.01% | 2640 |
|
|
2020
Q3 | $33K | Hold |
924
| – | – | ﹤0.01% | 2966 |
|
|
2020
Q2 | $22K | Buy |
924
+7
| +0.8% | +$165 | ﹤0.01% | 3156 |
|
|
2020
Q1 | $16K | Buy |
917
+417
| +83% | +$8.7K | ﹤0.01% | 3222 |
|
|
2019
Q4 | $9K | Hold |
500
| – | – | ﹤0.01% | 3543 |
|
|
2019
Q3 | $8K | Hold |
500
| – | – | ﹤0.01% | 3622 |
|
|
2019
Q2 | $10K | Hold |
500
| – | – | ﹤0.01% | 3562 |
|
|
2019
Q1 | $12K | Hold |
500
| – | – | ﹤0.01% | 3542 |
|
|
2018
Q4 | $10K | Sell |
500
-36
| -7% | -$653 | ﹤0.01% | 3538 |
|
|
2018
Q3 | $12K | Buy |
536
+36
| +7% | +$595 | ﹤0.01% | 3603 |
|
|
2018
Q2 | $8K | Buy |
+500
| New | +$9.42K | ﹤0.01% | 3744 |
|
Other funds holding DNLI
PNC Financial Services Group's DNLI Position: Q2 2026 in Review
PNC Financial Services Group reduced its Denali Therapeutics (DNLI) stake by 1.1% in Q2 2026, selling an estimated $2.01K and leaving 9,122 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.
PNC Financial Services Group first reported a position in DNLI in Q2 2018 and has held it in 33 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- PNC Financial Services Group held 9,122 shares of Denali Therapeutics worth $235K as of Q2 2026.
- PNC Financial Services Group sold 98 Denali Therapeutics shares in Q2 2026, an estimated $2.01K.
- Denali Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2353 holding.
- PNC Financial Services Group first reported a position in Denali Therapeutics in Q2 2018 and has held it in 33 quarters since.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.